JP2024509385A - アクチノヒビンバリアントポリペプチド及び関連方法 - Google Patents

アクチノヒビンバリアントポリペプチド及び関連方法 Download PDF

Info

Publication number
JP2024509385A
JP2024509385A JP2023550178A JP2023550178A JP2024509385A JP 2024509385 A JP2024509385 A JP 2024509385A JP 2023550178 A JP2023550178 A JP 2023550178A JP 2023550178 A JP2023550178 A JP 2023550178A JP 2024509385 A JP2024509385 A JP 2024509385A
Authority
JP
Japan
Prior art keywords
polypeptide
ovarian cancer
subject
cells
ovca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509385A5 (https=
Inventor
伸行 的場
デント，マシュー
Original Assignee
ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレーテッド filed Critical ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレーテッド
Publication of JP2024509385A publication Critical patent/JP2024509385A/ja
Publication of JP2024509385A5 publication Critical patent/JP2024509385A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023550178A 2021-03-04 2022-03-04 アクチノヒビンバリアントポリペプチド及び関連方法 Pending JP2024509385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156715P 2021-03-04 2021-03-04
US63/156,715 2021-03-04
PCT/US2022/070961 WO2022187851A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Publications (2)

Publication Number Publication Date
JP2024509385A true JP2024509385A (ja) 2024-03-01
JP2024509385A5 JP2024509385A5 (https=) 2025-01-06

Family

ID=83155364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550178A Pending JP2024509385A (ja) 2021-03-04 2022-03-04 アクチノヒビンバリアントポリペプチド及び関連方法

Country Status (9)

Country Link
US (1) US20240123026A1 (https=)
EP (1) EP4301389A4 (https=)
JP (1) JP2024509385A (https=)
CN (1) CN117098545A (https=)
AU (1) AU2022229597A1 (https=)
CA (1) CA3210629A1 (https=)
IL (1) IL305259A (https=)
MX (1) MX2023010183A (https=)
WO (1) WO2022187851A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145966B2 (en) 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148541A1 (en) * 2017-02-10 2018-08-16 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
EP3194973A1 (en) * 2014-09-17 2017-07-26 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148541A1 (en) * 2017-02-10 2018-08-16 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and related methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TUMOR BIOLOGY, JPN6025039929, 2017, pages 1 - 12, ISSN: 0005695736 *

Also Published As

Publication number Publication date
EP4301389A1 (en) 2024-01-10
CN117098545A (zh) 2023-11-21
WO2022187851A9 (en) 2022-09-29
MX2023010183A (es) 2023-11-22
WO2022187851A1 (en) 2022-09-09
CA3210629A1 (en) 2022-09-09
EP4301389A4 (en) 2025-03-12
AU2022229597A1 (en) 2023-10-19
IL305259A (en) 2023-10-01
US20240123026A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP7334177B2 (ja) 抗ｃｄ７３抗体及びその使用
CN111836644B (zh) 抗密蛋白18.2抗体及其用途
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
US11214615B2 (en) Anti-TIM-3 antibodies and uses thereof
US11655303B2 (en) Anti-CD39 antibody compositions and methods
EP3604338A1 (en) Anti-ox40 antibody and use thereof
KR20240130093A (ko) Cdh17 항체 및 암 치료 방법
ES2905531T3 (es) Anticuerpos anti-HER3 humano y usos de los mismos
EA022415B1 (ru) Биспецифичные молекулы, связывающие egfr/igfir
US20200165353A1 (en) Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer
KR20190095921A (ko) 항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
JP2022081519A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
JP7679380B2 (ja) Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
Qi et al. Hypoxia‐activated ADCC‐enhanced humanized anti‐CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity
JP2024509385A (ja) アクチノヒビンバリアントポリペプチド及び関連方法
US20240218051A1 (en) Modified binding polypeptides for optimized drug conjugation
US20260055200A1 (en) Combination therapies
JP2018503645A (ja) 標的への抗癌剤の送達を増加させる方法
EP4509142A1 (en) Fgfr4 as target in cancer treatment
KR20250089558A (ko) 항-αvβ6 항체 및 항체-약물 접합체 및 암 치료에서의 이의 용도
WO2025133322A1 (en) Cnx antigen-binding molecules
HK40031477A (en) Anti-cd73 antibodies and uses thereof
HK40017894A (en) Anti-ox40 antibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327